PBT434

PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc) . PBT434 has the potential for the research of Parkinson’s disease (PD) [1].

Product Specifications

CAS Number

[1232841-78-9]

Product Name Alternative

ATH434

UNSPSC

12352005

Target

α-synuclein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pbt434.html

Purity

98.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1N(C)C(CNCC)=NC2=C1C(Cl)=CC(Cl)=C2O.Br

Molecular Formula

C12H14BrCl2N3O2

Molecular Weight

383.07

References & Citations

[1]Finkelstein DI, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun. 2017 Jun 28;5 (1) :53.|[2]Bailey DK, Clark W, Kosman DJ. The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells. PLoS One. 2021 Jul 26;16 (7) :e0254794.